PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Health Decisions

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Health Decisions CEO to Address Adaptive Patient Enrollment at Brussels Conference - Dr. Michael Rosenberg will discuss how continuously adapting enrollment during studies prevents delays and setbacks
Health Decisions CEO to Address Adaptive Patient Enrollment at Brussels Conference

 

NewswireToday - /newswire/ - Durham, NC, United States, 2010/10/01 - Dr. Michael Rosenberg will discuss how continuously adapting enrollment during studies prevents delays and setbacks.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Dr. Michael Rosenberg, CEO of full-service contract research organization (CRO) Health Decisions, will explore adaptive techniques for ensuring timely enrollment of clinical studies at the first annual Achieving Operational Efficiency in Clinical Trials conference, held October 6 – 7, 2010 in Brussels, Belgium.

Entitled “Adaptive Enrollment: Outlining ways to prevent delays and trial setbacks by managing with real-time information during the study,” Dr. Rosenberg’s presentation will include the following topics:

• Understanding why enrollment is the critical factor in determining study success and why it is such a pervasive challenge;
• Defining systems and information types needed to effectively and efficiently manage a trial in real time;
• Identifying opportunities to improve on-time enrollment statistics from the current 10 percent industry standard to 80 percent;
• Assessing ‘agile enrollment’ vs. current ‘best practices’ to uncover novel adaptive solutions;
• Using performance metrics to continuously track site-specific limitations and quickly resolve recruitment setbacks;
• Uncovering the ways in which adaptive monitoring can optimize patient retention.

“Adaptive design is steadily gaining credibility in the drug and device development industries, but its core principles are just as impactful when applied to study operations, if not more so,” said Dr. Rosenberg. “This is especially true for patient enrollment, regardless of study size, complexity, or therapeutic area. By leveraging timely flows of key information to continuously improve the operational variables driving enrollment, setbacks can be avoided or surmounted, resulting in faster, more efficient studies with more reliable outcomes.”

To learn more about adaptive enrollment and the topics discussed in Dr. Rosenberg’s presentation, you can download a free white paper from Health Decisions, Ten Steps to Faster Enrollment at the URL accompanying this press release.

“Adaptive Enrollment” takes place Thursday, October 7 at 15:30 (3:30 pm) CET, initiating the portion of the conference dedicated to anticipating the surge in adaptive design use and assessing the implications of operational efficiency.

Achieving Operational Efficiency in Clinical Trials was developed to bring clinical operations executives together to explore the newest and best solutions to today’s operational challenges and to provide heightened perspective about strategies that work. The conference’s first-ever meeting will be held at the Thon Hotel Bristol Stephanie in Brussels, Belgium October 6 – 7, 2010. The full event program is available online at the Achieving Operational Efficiency in Clinical Trials website.

About Health Decisions
Health Decisions (healthdec.com) is a global clinical research organization (CRO) committed to helping drug and device companies achieve greater success. Our sponsors rely on us to help them prove the value of their pipelines both faster and with the smartest possible allocation of funds. Through Agile Clinical Development—a strategic combination of adaptive design and adaptive operations—Health Decisions optimizes every facet of clinical research from design protocol to the most detailed day-to-day management, so sponsors can make the most of competitive market opportunities.

Health Decisions is headquartered in Durham, NC, with over twenty years of experience helping sponsors achieve success in Phase I-IV trials across all major therapy areas. For more information, please visit the company's website at the URL accompanying this press release.

About About Achieving Operational Efficiency in Clinical Trials
Achieving Operational Efficiency in Clinical Trials provides a forum for clinical operations executives to learn the newest and best solutions to the top operational challenges being faced today, including the optimization of patient recruitment, partnerships, study design and quality. Through practical case studies, expert-led roundtable discussions, and extensive networking opportunities, the event presents an opportunity for sponsors and CROs to gain heightened perspectives about successful strategies for producing better results whilst becoming more efficient.

The first annual conference will be held Wednesday 6 – Thursday 7 October 2010 in Brussels, Belgium at Thon Hotel Bristol Stephanie. For more information, please visit the conference website.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Health Decisions

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Health Decisions CEO to Address Adaptive Patient Enrollment at Brussels Conference

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Katie Hendrick - HealthDec.com 
919-967-1111 x116 khendrick[.]healthdec.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Health Decisions securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Health Decisions / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

BD Expands Suite of Blood Culture Offerings with New BD BACTEC™ Standard Aerobic & Standard Anaerobic Plastic Bottles
Twist Bioscience Collaborates with Synbio Technologies to Supply Long DNA to Customers
FDA Grants Priority Review and Breakthrough Therapy Designation for Zelboraf (vemurafenib) in Erdheim-Chester Disease with BRAF V600 Mutation
Ipsen Receives Positive CHMP Opinion for Approval of Xermelo® (telotristat Ethyl)
BD Receives FDA 510(k) Clearance for New Immunological Diagnostic System
Positive Phase III Results for Genentech’s Emicizumab in Hemophilia A Published in The New England Journal of Medicine
Somatuline® Autogel® 120 Mg Receives Japanese Approval for A New Indication for the Treatment of Gastro-entero-pancreatic Neuroendocrine Tumors
OTC Topical Drugs Market Size will Grow Profitably in the Near Future 2017-2025 Finds PMR
Bioinformatics Market Size to Expand at 20.4% CAGR through 2020 Reports Persistence Market Research
Australia Nitric Acid Market Expected to Reach at Value of $1.3B by 2024 End Says PMR
Commodity Chemicals Market Projected to be Resilient by 2020 Says Persistence Market Research
Cell Expansion Market Set to Garner Staggering Revenues by 2025 Reports PMR
Soft Tissue Sarcoma Treatment Market Revenue Predicted To Go Up by 2025 Finds Persistence Market Research
Persistence Market Research Publishes Biopharmaceutical Membrane Filtration Market Forecast Over 2017-2025
Global Tablet Processing & Packaging Equipment Market to Reach USD 5,268.8 Million by 2022

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  La Bella Bakery Artisan Bakery Arizona

Visit  RightITnow Ltd





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)